-transparent.png){kind=logo}
From December 1979 to August 1982 158 patients were registered for an adjuvant chemotherapy (CT) study COSS -80. To compare the effect of cisplatin (CPL) to that of the drug combination bleomycin, cyclophosphamide, and dactinomycin (BCD), patients were randomized to receive either drug(s) within a course of sequential multidrug CT including doxorubicin and high-dose methotrexate (HDMTX). Definite surgery was done 10-18 weeks after the start of CT. Patients were randomized a second time to receive or not to receive fibroblast interferon in addition to CT beginning at week 16. At a median observation time of 19.5 months (range, 4-34 months), 116 (73%) of 158 patients were continuously disease-free (CDF). After exclusion of 42 patients because of some deviation in history and/or management, 86 (74%) of 116 patients actually were CDF with a 30-month calculated CDF-rate of 68%. There was no difference in CDF rates in the patients receiving BCD versus CPL or receiving interferon versus no interferon. Whereas, in comparison to the previous study COSS -77, the over-all increase in CDF rate does not reach statistical significance, it does, however, for the younger (less than or equal to 12 years) and for male patients, which is assumed to be the effect of increasing the methotrexate dose from 6 to 12 g/m2 in the COSS -80 study.
K Winkler, and
G Beron, and
R Kotz, and
M Salzer-Kuntschik, and
J Beck, and
W Beck, and
W Brandeis, and
W Ebell, and
R Erttmann, and
U Göbel
February 1992,
Journal of the National Cancer Institute,
K Winkler, and
G Beron, and
R Kotz, and
M Salzer-Kuntschik, and
J Beck, and
W Beck, and
W Brandeis, and
W Ebell, and
R Erttmann, and
U Göbel
July 2007,
Current opinion in oncology,
K Winkler, and
G Beron, and
R Kotz, and
M Salzer-Kuntschik, and
J Beck, and
W Beck, and
W Brandeis, and
W Ebell, and
R Erttmann, and
U Göbel
May 1985,
Orthopedics,
K Winkler, and
G Beron, and
R Kotz, and
M Salzer-Kuntschik, and
J Beck, and
W Beck, and
W Brandeis, and
W Ebell, and
R Erttmann, and
U Göbel
October 1974,
Journal of the Medical Association of the State of Alabama,
K Winkler, and
G Beron, and
R Kotz, and
M Salzer-Kuntschik, and
J Beck, and
W Beck, and
W Brandeis, and
W Ebell, and
R Erttmann, and
U Göbel
September 1991,
Clinical orthopaedics and related research,
K Winkler, and
G Beron, and
R Kotz, and
M Salzer-Kuntschik, and
J Beck, and
W Beck, and
W Brandeis, and
W Ebell, and
R Erttmann, and
U Göbel
June 1989,
Journal of chemotherapy (Florence, Italy),
K Winkler, and
G Beron, and
R Kotz, and
M Salzer-Kuntschik, and
J Beck, and
W Beck, and
W Brandeis, and
W Ebell, and
R Erttmann, and
U Göbel
January 1986,
Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer,
K Winkler, and
G Beron, and
R Kotz, and
M Salzer-Kuntschik, and
J Beck, and
W Beck, and
W Brandeis, and
W Ebell, and
R Erttmann, and
U Göbel
January 1983,
Journal of cancer research and clinical oncology,
K Winkler, and
G Beron, and
R Kotz, and
M Salzer-Kuntschik, and
J Beck, and
W Beck, and
W Brandeis, and
W Ebell, and
R Erttmann, and
U Göbel
February 1978,
Cancer treatment reports,
K Winkler, and
G Beron, and
R Kotz, and
M Salzer-Kuntschik, and
J Beck, and
W Beck, and
W Brandeis, and
W Ebell, and
R Erttmann, and
U Göbel
February 1988,
European journal of cancer & clinical oncology,
